Nektar prevails in legal battle with Lilly over broken rezpeg partnership

rezpegPositive

AI Analysis

Summary

Nektar Therapeutics won a legal battle against Eli Lilly, with a jury awarding $90 million in damages for alleged mishandling of their shared autoimmune drug rezpeg analysis.

Outcome Details

Jury awarded Nektar $90 million in damages against Eli Lilly for breach of partnership agreement regarding rezpeg analysis

Importance:6/10

Sentiment:

0.85

litigationpartnership disputedamages awardautoimmune

Related Companies

$LLY

Read the original article

Published by BioSpace on September 25, 2026 2:04 PM

Read Original